Gilead Sciences Inc GILD:NASDAQ

Last Price$67.17Cboe Real-Time Last Sale as of 12:43PM ET 6/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.81(1.22%)
Bid (Size)$67.16 (400)
Ask (Size)$67.18 (300)
Day Low / High$66.12 - 67.45
Volume2.0 M

View Biotechnology IndustryPeer Comparison as of 06/17/2019


Gilead Sciences Inc ( NASDAQ )

Price: $67.17
Change: +0.81 (1.22%)
Volume: 2.0 M
12:43PM ET 6/17/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Celgene Corp ( NASDAQ )

Price: $97.46
Change: +0.95 (0.98%)
Volume: 1.5 M
12:43PM ET 6/17/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Amgen Inc ( NASDAQ )

Price: $178.10
Change: +2.02 (1.15%)
Volume: 631.7 K
12:42PM ET 6/17/2019

Read more news Recent News

Gilead Sciences' Kite Reports Updated Yescarta Data, KTE-X19 Phase 1 Trial Results
12:29PM ET 6/03/2019 MT Newswires

Gilead Sciences' Kite subsidiary released updated data from its Yescarta trial, showing more than 50% of patients still alive after two years. Yescarta had...

Gilead Sciences Unit to Collaborate with Humanigen on Combo Drug Treatment for Lymphoma
9:40AM ET 5/31/2019 MT Newswires

Gilead Sciences (GILD) said Friday its Kite unit has formed a partnership with Humanigen to study lenzilumab, an investigational anti-GM-CSF monoclonal...

Gilead Sciences Names Johanna Mercier as Chief Commercial Officer
9:02AM ET 5/29/2019 MT Newswires

Gilead Sciences (GILD) said Wednesday it has named Johanna Mercier as its chief commercial officer and said she will become a member of the company's...

Close Update: Stocks Slump Late After Posting Earlier Gains to Kick Off Shortened Trading Week
4:40PM ET 5/28/2019 MT Newswires

Stocks closed lower Tuesday, giving up gains earlier in the session, as the market began the shortened trading week on a sour note. The Dow Jones...

View all Commentary and Analysis

AstraZeneca Gives Detailed Data From Calquence Leukemia Study
8:51AM ET 6/17/2019 Zacks

AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in...

GILD vs. ILMN: Which Stock Is the Better Value Option?
8:30AM ET 6/14/2019 Zacks

GILD vs. ILMN: Which Stock Is the Better Value Option?

Akero Therapeutics Readies $75 Million IPO
1:11PM ET 6/13/2019 Seeking Alpha

June 2019 Stock Considerations
3:24AM ET 6/13/2019 Seeking Alpha

Company Profile

Business DescriptionGilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. View company web site for more details
Address333 Lakeside Drive
Foster City, California 94404
Number of Employees11,000
Recent SEC Filing06/07/2019CT ORDER
Chairman & Chief Executive OfficerDaniel O'Day
CFO, Chief Accounting Officer & Executive VPRobin L. Washington
Chief Scientific OfficerJohn G. McHutchison
Secretary, Chief Compliance Officer & Executive VPBrett A. Pletcher

Company Highlights

Price Open$66.47
Previous Close$66.36
52 Week Range$60.32 - 79.61
Market Capitalization$85.6 B
Shares Outstanding1.3 B
SectorHealth Technology
Current Dividend / Yield$0.63 / 3.80%
Dividend Ex-Date06/13/2019
Dividend Pay-Date06/27/2019
Dividend Yield 5 Year AverageN/A
Next Earnings Announcement07/24/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings14.65
Earnings per Share$4.83
Beta vs. S&P 500N/A
Revenue$22.2 B
Net Profit Margin26.39%
Return on Equity26.82%

Analyst Ratings as of 06/07/2019

Consensus RecommendationConsensus Icon
Powered by Factset